Company: INKT
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001193125-25-282905
Chunk: 6

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 2
Chunk 6
---
 balstilimab (anti-PD-1), ramucirumab, and paclitaxel. The trial, expected to enroll approximately 38 patients with advanced, unresectable, or metastatic disease, is a strategic priority for the Company. The inclusion of agenT-797 in this regimen reflects growing clinical interest following the durable responses observed in Phase 1, including the Nature Oncogene complete and partial responder cases, and aims to determine whether similar benefits can be achieved in 2L gastric cancer. Encouraging activity for